


BACKGROUND


Human induced pluripotent stem cells (hiPSCs) have generated significant interest in various medical and biomedical fields due to their capacity for self-renewal and trilineage differentiation [1-3]. To achieve clinically relevant hiPSC numbers, scalable bioreactor-based processes are required. While there exist studies in scaling up the expansion of hiPSCs, the use of conventional bioreactors with horizontal-impeller, paddle, or rocking-wave mixing mechanisms have demonstrated several challenges including unfavourable hydrodynamic environments and poor scalability. Additionally, many of these processes require large static seed trains and achieve only moderate cell fold increases [4-6]. An alternative to these traditional geometries is the Vertical-Wheel® (VW) bioreactor. We have previously demonstrated that the VW bioreactor combines radial and axial mixing to uniquely produce uniform distributions of hydrodynamic forces which can be favourable for the cultivation of shear-sensitive cell types including hiPSCs grown as cell aggregates [7].




PROJECT OVERVIEW

- The objective of this project was to demonstrate that the VW bioreactor could be used to overcome current challenges associated with scaling-up production of hiPSCs.
- Bottlenecks associated with **inoculation**, **expansion**, and **aggregate dissociation** phases were investigated at the 0.1L scale.
- Protocol robustness was validated by **serial passaging** hiPSCs from a 0.1 L VW bioreactor into a secondary 0.1 L and 0.5 L VW bioreactor. Successful culture was defined by growth kinetics, aggregate morphology, and biological testing.


COMPARING SINGLE CELL INOCULATION IN DIFFERENT GEOMETRIES




IMPROVING CELL EXPANSION USING DIFFERENT FEEDING REGIMES



DEVELOPING AN IN-VESSEL AGGREGATE DISSOCIATION PROTOCOL



VALIDATING THE OPTIMIZED PROTOCOLS VIA SERIAL PASSAGING



CONCLUSIONS

In this study, various bioprocess bottlenecks associated with the large scale expansion of hiPSCs were addressed. This included developing strategies to use single cell inoculation, methods to improve cell fold expansion using different feeding regimes, and a protocol for in-vessel aggregate dissociation. Under optimized single-cell inoculation conditions, we achieved a 32-fold expansion in six days with uniform aggregate size distribution. We also achieved recoveries of over 90% using optimized harvesting parameters while maintaining positive expression of pluripotency markers. Additionally, we demonstrated that cell growth and pluripotency were maintained while serial passaging using these protocols. Through these findings, we demonstrated that Vertical-Wheel bioreactors can be used to overcome the current challenges associated with scaling-up production of hiPSCs.

REFERENCES

- [1] Shi Y, Inoue H, Wu JC, et al. Induced pluripotent stem cell technology: A decade of progress. Nat Rev Drug Discov 2017.
- [2] Scudellari M. How iPS cells changed the world. Nature 2016.
- [3] Revilla A, González C, Iriando A, et al. Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine. J Tissue Eng Regen Med 2016.
- [4] Rodrigues CAV, Silva TP, Nogueira DES, et al. Scalable culture of human induced pluripotent cells on microcarriers under xeno-free conditions using single-use vertical-wheel bioreactors. J Chem Technol Biotechnol 2018;93:3597–3606
- [5] Nogueira DES, Rodrigues CAV, Carvalho MS, et al. Strategies for the expansion of human induced pluripotent stem cells as aggregates in single-use Vertical-Wheel™ bioreactors. J Biol Eng 2019;13.
- [6] de Sousa Pinto D, Bandejas C, de Almeida Fuzeta M, et al. Scalable Manufacturing of Human Mesenchymal Stromal Cells in the Vertical-Wheel Bioreactor System: An Experimental and Economic Approach. Biotechnol J 2019;14.
- [7] Borys BS, So T, Colter J, et al. Optimized serial expansion of human induced pluripotent stem cells using low-density inoculation to generate clinically relevant quantities in vertical-wheel bioreactors. Stem Cells Transl Med 2020;9:1036.

ACKNOWLEDGMENTS

